These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10194831)

  • 1. Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness.
    Da Villa G; Sepe A
    Vaccine; 1999 Mar; 17(13-14):1734-8. PubMed ID: 10194831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term epidemiological survey of hepatitis B virus infection in a hyperendemic area (Afragola, southern Italy): results of a pilot vaccination project.
    Da Villa G; Piccinino F; Scolastico C; Fusco M; Piccinino R; Sepe A
    Res Virol; 1998; 149(5):263-70. PubMed ID: 9879603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for the infant and adolescent vaccination programmes in Italy.
    Da Villa G
    Vaccine; 2000 Feb; 18 Suppl 1():S31-4. PubMed ID: 10683541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis.
    Bloom BS; Hillman AL; Fendrick AM; Schwartz JS
    Ann Intern Med; 1993 Feb; 118(4):298-306. PubMed ID: 8420448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B vaccination: universal vaccination of newborn babies and children at 12 years of age versus high risk groups. A comparison in the field.
    Da Villa G; Picciottoc L; Elia S; Peluso F; Montanaro F; Maisto T
    Vaccine; 1995 Sep; 13(13):1240-3. PubMed ID: 8578810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits.
    Boccalini S; Taddei C; Ceccherini V; Bechini A; Levi M; Bartolozzi D; Bonanni P
    Hum Vaccin Immunother; 2013 May; 9(5):1119-28. PubMed ID: 23376840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A tool to measure the economic impact of Hepatitis B elimination: A case study in Saudi Arabia.
    Sanai FM; Alghamdi M; Dugan E; Alalwan A; Al-Hamoudi W; Abaalkhail F; AlMasri N; Razavi-Shearer D; Razavi H; Schmelzer J; Alfaleh FZ
    J Infect Public Health; 2020 Nov; 13(11):1715-1723. PubMed ID: 32988769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges.
    Mele A; Tosti ME; Mariano A; Pizzuti R; Ferro A; Borrini B; Zotti C; Lopalco P; Curtale F; Balocchini E; Spada E;
    Clin Infect Dis; 2008 Mar; 46(6):868-75. PubMed ID: 18269332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-benefit analysis of the introduction of mass vaccination against hepatitis B in Italy.
    Demicheli V; Jefferson TO
    J Public Health Med; 1992 Dec; 14(4):367-75. PubMed ID: 1489561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of prenatal screening and immunization for hepatitis B virus.
    Arevalo JA; Washington AE
    JAMA; 1988 Jan; 259(3):365-9. PubMed ID: 2961895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B prevention in Europe: a preliminary economic evaluation.
    Van Damme P; Tormans G; Beutels P; Van Doorslaer E
    Vaccine; 1995; 13 Suppl 1():S54-7. PubMed ID: 7571833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-benefit analysis of the Polish hepatitis B prevention programme.
    Wiewióra-Pilecka D
    Vaccine; 2000 Feb; 18 Suppl 1():S52-4. PubMed ID: 10683548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of viral hepatitis B in Italy.
    Crovari P
    Vaccine; 1995; 13 Suppl 1():S26-30. PubMed ID: 7571823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A cost-effectiveness analysis of vaccination against the hepatitis B virus].
    Antoñanzas F; Forcén T; Garuz R
    Med Clin (Barc); 1992 Jun; 99(2):41-6. PubMed ID: 1630178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-benefits of vaccination against hepatitis B in hospital personnel in Venezuela].
    Fernández Barboza R; Rivero D; Echeverría B; Machado IV
    Bol Oficina Sanit Panam; 1991 Jul; 111(1):16-23. PubMed ID: 1834080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy.
    Bonanni P; Pesavento G; Bechini A; Tiscione E; Mannelli F; Benucci C; Nostro AL
    Vaccine; 2003 Jan; 21(7-8):685-91. PubMed ID: 12531340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global programme for control of hepatitis B infection.
    Kane M
    Vaccine; 1995; 13 Suppl 1():S47-9. PubMed ID: 7571830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of prenatal screening and vaccination against hepatitis B virus--the case of Belgium.
    Tormans G; Van Damme P; Carrin G; Clara R; Eylenbosch W
    Soc Sci Med; 1993 Jul; 37(2):173-81. PubMed ID: 8351532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Economic evaluation and prediction of hepatitis B immunization strategy in Shenzhen, China].
    Sun PP; Zhang SX; Xia Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jul; 52(7):743-747. PubMed ID: 29996303
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.